TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>/=18 years~* Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)~* Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria~* Total Cumulative Illness Rating Scale (CIRS) \> 6 and/or creatinine clearance \< 70 ml/min~Exclusion Criteria:~* Prior CLL therapy~* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)~* History of other malignancy unless the malignancy has been in remission without treatment for \>/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone~* Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing~* Patients with active infection requiring systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- obinutuzumab + chlorambucil (GClb) (Type: EXPERIMENTAL): Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
- rituximab + chlorambucil (RClb) (Type: ACTIVE_COMPARATOR): Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
- Chlorambucil (Clb) (Type: ACTIVE_COMPARATOR): Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Implant Thread Design on Implant Stability Quotient (ISQ) in Early Healing Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Missing two or more teeth with a desire to receive an implant-supported or implant-assisted tooth replacement~* Healed maxillary or mandibular edentulous site for implant placement~* Sufficient bone volume in the site to allow implant placement without the need for bone augmentation~Exclusion Criteria:~* Systemic disease, medication, or habit known to negatively influence bone healing and/or dental implant success~  * Poorly controlled diabetes (HbA1c \> 8%)~ * History of bisphosphonate use~ * History of head \& neck radiation therapy affecting the proposed implant site~ * History of smoking \>10 cigarettes/day (within past 12 months)~ * Current use of medications that adversely affect healing (e.g. corticosteroids, chemotherapeutic drugs)~ * Immune compromised condition (resulting from disease or treatment)~* Insufficient bone volume for dental implant placement~* Otherwise contraindicated to undergo periodontal / oral / implant surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AnyRidge Implant (Type: EXPERIMENTAL): Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
- EZ Plus Implant (Type: ACTIVE_COMPARATOR): Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Potential subjects will be adult patients admitted to medical and surgical services at BWH and MGH, likely to be discharged back to the community, and whose PCP belongs to one of the Partners Community Healthcare, Inc. (PCHI) primary care practices that has met Primed criteria for being a PCMH, admits at least 2 patients to BWH or MGH, and has agreed to participate. Primed criteria are a standard set of requirements that cover 6 essential building blocks of PCMH practices: electronic health record, patient portal, team-based care, practice redesign, care management, and identification of high-risk patients. We estimate that of the approximately 300 PCHI adult primary care practices, 150 of them will meet PCMH criteria during the study and that 20 of them will qualify and be willing to participate in the study. We estimate that 12,000 such patients will be admitted to BWH and MGH over the 18-month study period, of which we will enroll 1700 patients. These patients are broadly representative of hospitalized patients and include several vulnerable populations, including the elderly (33% 65 or older), patients with multiple chronic conditions (47% with Elixhauser comorbidity score 5 or more), and racial and ethnic minorities (14% African American, 13% Latino).~Exclusion Criteria:~1. Likely discharge to a location other than home (or to a caregiver's home)~2. Police custody~3. No telephone or homeless~4. Previous enrolment in the study~5. Patient unable to communicate in either English or Spanish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multi-Model Intensive Discharge Program (Type: EXPERIMENTAL): Multi-Model Intensive Discharge Program
- Usual Care (Type: NO_INTERVENTION): Usual Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus diagnosed at least 3 months with FPG level \<=240mg/dL and HbA1c between 6.5% and 10% inclusive.~* Must be diet controlled - OR - taking a single oral antidiabetic agent (other than thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to the study.~* Must have a BMI:\<=35kg/m2, 20 to 70 years of age inclusive.~* Woman must be of non-childbearing potential.~Exclusion criteria:~* Positive test result for either syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, or HTLV-1 antibody.~* Clinically significant hepatic enzyme elevation.~* History of metabolic disease other than T2DM.~* Previous use of insulin as a treatment for diabetes within 3 months.~* History of severe gastrointestinal disease.~* Clinically significant cardiovascular disease.~* Significant renal disease as defined by screening lab test.~* History of drug (including albumin or albumin containing agents) allergy.~* History of alcohol or drug abuse.~* Donation of blood in excess of 400mL within previous 4 months.~* Previously received any GLP-1 mimetic or any other albumin-containing products.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Subjects receiving GSK716155 + placebo (Type: EXPERIMENTAL): Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Definite diagnosis of multiple sclerosis by the McDonald criteria.~* Patients with relapsing remitting MS or secondary progressive MS are eligible.~* 1-5 gadolinium enhancing (Gd+) lesions on the first Screening MRI or relapse in the previous 2 years, or disease worsening in the previous 2 years~* Clinically stable for \> 1 month before screening evaluation and during screening. Patients who are stable on approved therapy are eligible only if they have intolerable side effects or other medical reasons for discontinuing approved therapy.~* Off interferon for \> 1 month before screening evaluation.~* Off immunosuppressive and cytotoxic therapy (e.g. mitoxantrone, cladrabine) \>12 months or \> 6 months with CD4 count \> 400.~* EDSS ≥ 2.5 and \< 7.0.~* Female or male, age \> 18 years.~* Able to give informed consent.~* WBC and platelets in normal range, hemoglobin \> 10.0 g/dl.~* AST, ALT, bilirubin \< upper limit of normal.~* Creatinine \< upper limit of normal.~* CPK \< upper limit of normal.~Exclusion Criteria:~* High-dose corticosteroids (e.g. \>500 mg methylprednisolone or equivalent) within previous month.~* \>5 Gd+ lesions on the first Screening MRI.~* Previous vaccine therapy, stem cell transplantation or total lymphoid radiation.~* Glatiramer within previous 12 months.~* Treatment with any statin in the previous 6 months or elevated cholesterol that requires treatment with a statin.~* Pregnant or lactating women.~* Unwilling to use a medically acceptable form of birth control.~* History of positive test for HIV, hepatitis B or hepatitis C.~* Clinically significant ECG abnormalities.~* Medical condition or social circumstances that would in the opinion of the investigator prevent full participation in the trial or evaluation of study endpoints.~* Implanted pacemakers, defibrillators or other metallic objects on or inside the body that limit performing MRI scans.~* History of intolerable adverse events with statin therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less)~* Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these medications in the past 2 weeks~* Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10 pmol/L)~Exclusion Criteria:~* Systolic blood pressure (SBP) \< 110 mm Hg at screening or pre-randomization~* Heart rate \< 50 beats per minute (bpm) or \> 90 bpm at screening or pre-randomization~* Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial Flutter~* Estimated glomerular filtration rate (eGFR) \< 15 ml/min/1.73 m2~* Ventricular assist device or prior heart transplant~* Prior solid organ transplant~* Body weight \< 45 kg or ≥ 140 kg~* Low quality echocardiographic visualization windows and image acquisition~* Permanent paced rhythm (VVI, DDD or BiV pacing)~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/BMS-986231/NTG (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- Placebo/NTG/BMS-986231 (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- NTG/Placebo/BMS-986231 (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- NTG/BMS-986231/Placebo (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- BMS-986231/Placebo/NTG (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- BMS-986231/NTG/Placebo (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female cigarette smokers over the age of 18 years who are not willing/able to quit smoking within the next month but who are willing to attempt to reduce their smoking to work toward a quit attempt within the next 3 months.~* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit, with no continuous period of abstinence greater than 3 months in the past year and who have an exhaled carbon monoxide (CO) \>10 ppm at screening.~* Subjects with mild to moderate depression or anxiety may be included if their condition is stable.~Exclusion Criteria:~* Subjects with a history of a suicide attempt or any suicidal behavior in the past two years.~* Subjects with severe depression or anxiety.~* Subjects with psychosis, panic disorder, bipolar disorder, post traumatic stress disorder (PTSD), or schizophrenia.~* Subjects with alcohol or substance abuse or dependence (except nicotine) unless in full remission for at least 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline Tartrate (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening~Exclusion Criteria:~* Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.~* History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Nursing homes will be eligible to participate if they meet the following criteria:~* Licensed nursing home in Orange County or Southern Los Angeles County serving adults~* Minimal use of chlorhexidine bathing\*~* Minimal use of nasal decolonization\* \*Minimal use defined as \<15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay.~Exclusion Criteria~Nursing homes will not be eligible to participate if they meet the following criteria:~* Facilities routinely using decolonization~* Dedicated psychiatric nursing homes~* Facilities with a resident population with \>=20% combative patients~* Pediatric facilities~Note: in any participating nursing home, residents with active end-of-life comfort care only measures are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decolonization (Type: ACTIVE_COMPARATOR): Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
- Routine Bathing (Type: NO_INTERVENTION): Routine bathing per facility protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Naturally or surgically menopausal~* Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse)~Exclusion Criteria:~* Known sensitivity or contraindication to estrogens or progestins~* History or current diagnosis endometrial hyperplasia~* Recent history of vaginal bleeding of unknown cause~* Recent history or diagnosis of endometriosis~* Any contraindication to estrogen therapy

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inadequate response to conventional therapy including corticosteroids or are intolerant to, or have medical contraindications for conventional therapies~* UC diagnosed prior to screening, based on a biopsy collected at endoscopy~* Moderate to severe active UC with total Mayo score of 6 to 12, inclusive at baseline, and endoscopic Mayo sub-score, greater than or equal to 2~* Adenomatous polyps removed within last 5 years or at the screening visit prior to the first drug treatment~* Extensive colitis for ≥ 8 years, or disease limited to the left side of the colon for ≥10 years should have a colonoscopy to exclude the presence of dysplasia within 1 year prior to study inclusion or a colonoscopy to exclude the presence of malignancy at the screening visit~* No history of untreated latent or active Tuberculosis (TB) prior to screening~* Negative stool results for enteric pathogens~Exclusion Criteria:~* History of asthma~* History of autoimmune diseases~* History of hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab treatment (Type: EXPERIMENTAL): Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* A male or female between, and including, 18 and 60 years of age at the time of the first vaccination.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* If the subject is female, she must be of non-childbearing potential.~Exclusion criteria:~* Administration of any vaccine during the period starting 15 days before the first administration of the study vaccine and ending 21 after the second one.~* Administration of an influenza vaccine other than the study vaccines during the entire study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the study vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination~* History of hypersensitivity to vaccines.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or during the study.~* lactating women~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete